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Abstract Both estrogen receptor K (ERK) and the recently
identified ERL are nuclear receptors that are activated by
estrogen. It was reported that ERK and ERL form heterodimers.
Here, we show that they activate transcription independently
rather than synergistically via estrogen response elements (ERE).
To show the cross-talk between ERK and ERL, we utilized
dominant negative mutants of ERs constructed by C-terminal
truncation. Interestingly, ERK1^530 inhibited transactivation
not only by ERK but also by ERL, whereas ERL1^481 inhibited
transactivation by ERK as well as by ERL. The GST pull-down
assay also demonstrated the cross-interaction of these mutants
with wild-type ERK and ERL. Thus, we found dominant negative
mutants that block both ERK and ERL signaling pathways.
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1. Introduction
Estrogen is known to exert striking e¡ects on the growth
and development of the reproductive organs. It is assumed
that its diverse e¡ects are mediated in major part by the estro-
gen receptor (ER), a member of the nuclear receptor super-
family [1,2].
Recently, a second ER, namely ERL, has been isolated in
rat prostate [3], human testis [4] and mouse ovary [5]. ERL
displays high a⁄nity binding of 17L-estradiol (E2). The DNA
binding domain of ERL is almost identical to ERK, implying
that both ERK and ERL share the same DNA response ele-
ment. More recently, the heterodimer complex of ERK and
ERL has been shown in vitro and in vivo irrespective of ligand
binding. Furthermore, ERK/ERL heterodimers bind to an
ERE with an a⁄nity similar to that of the ERK homodimer
and greater than that of the ERL homodimer [6,7]. However,
there is no functional evidence of ERK/ERL heterodimers in
vivo. On the other hand, in the case of an ERK C-terminal
truncation mutant, ERK1^530 was reported to have a domi-
nant negative activity against wild-type ERK [8]. The constit-
utive negative phenotype of ERK1^530 is at least partly be-
cause its activation function 2 (AF-2) is eliminated.
In order to investigate the cross-talking possibility of ERK
and ERL by their functional heterodimerization, we con-
structed ERK1^530 and its equivalent mutant of ERL
(ERL1^481) to study the inhibition of each mutant against
wild-type ERK and ERL. As a result, ligand-dependent trans-
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Fig. 1. E2-dependent transactivation of co-expressed ERK and ERL.
A: Transactivation of the ERE-GCAT reporter by ERK and ERL.
COS-7 cells were transfected with 2 Wg of ERE-GCAT reporter
plasmid and 10 ng of wild-type ER expression vectors. The trans-
fected cells were incubated for 24 h in the absence (3) or presence
(+) of 1037 M E2. Then CAT activities were determined and nor-
malized relative to the L-galactosidase activities expressed by the
PCH110 internal control vector. CAT activities are indicated as the
fold induction of the control, and are presented as means+standard
deviations calculated from three independent experiments. B:
pCXN2-hERK and pCXN2-hERL were co-transfected with EREG-
CAT in COS-7 cells in varying ratios from 0 to 10 ng.
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activation of ERK and ERL on an ERE was suppressed by
each of their C-terminal truncated mutants, suggesting the
cross-talking function of ERK/ERL heterodimers in vivo.
2. Materials and methods
2.1. Plasmid construction
The ERK cDNA originating from HEG0 [9] was cloned into the
pCXN2 expression vector [10] to construct pCXN2-hERK. The ERK
cDNA encoding amino acids 117^595 was cloned into pGEX4T-2
(Pharmacia) to construct GST-hERK. The RT-PCR product of ERL
cDNA (nucleotides 1^1740) [11] was inserted into pCXN2 and into
pGEX4T-2 (Pharmacia) to construct pCXN2-hERL and GST-hERL,
respectively. The PCR-ampli¢ed products of ERL1^481 (nucleotides
99^1541) and ERK1^530 (cDNA fragment encoding amino acids 1^
530) were cloned into pCXN2 to construct pCXN2-hERL1^481 and
pCXN2-hERK1^530, respectively. Construction of ERE-GCAT was
described elsewhere [12]. All constructs were veri¢ed by sequencing.
2.2. DNA sequence and analysis
The nucleotide sequences were determined by sequencing of both
strands of alkaline-denatured plasmid DNA using the BcaBest
sequencing kit (TaKaRa Co.). The obtained DNA sequence was
compiled and analyzed using DNASIS computer programs (Hitachi
Co.).
2.3. Cell transfection and preparation of whole cell extracts
COS-7 cells were maintained in Dulbecco’s modi¢ed Eagle’s me-
dium (DMEM) without phenol red, supplemented with 10% dextran-
coated charcoal-treated fetal calf serum [13]. 5U105 cells in 10 cm
Petri dishes were transfected with a total of 20 Wg of plasmids using
calcium phosphate [14]. Cells were harvested 36 h after transfection
and whole cell extracts were prepared by freeze-thawing and diluted in
100 Wl of TEG bu¡er (10 mM Tris, pH 7.5, 1.5 mM EDTA, 10%
glycerol).
2.4. Chloramphenicol acetyltransferase (CAT) assays
The CAT assay was performed as described [15]. Brie£y, 5U105 of
COS-7 cells were transfected with a total of 15 Wg of DNA. 2 Wg of
ERE-GCAT reporter plasmid was co-transfected with indicated
amounts of receptor expression vectors. All assays were performed
in the presence of 2 Wg of PCH110 (Pharmacia), a L-galactosidase
expression vector used as internal control to normalize for variations
in transfection e⁄ciency. The total amount of DNA and expression
vectors for transfection was adjusted using pGEM3Zf (Promega) and
pCXN2, respectively. After 12 h incubation with the calcium phos-
phate-precipitated DNA, the cells were washed with fresh medium
and incubated for an additional 24 h in the absence or presence of
1037 M E2. Cell extracts were prepared by freeze-thawing and assayed
for CAT after normalization for L-galactosidase activity.
2.5. Glutathione S-transferase (GST) pull-down assay
ERK and ERL proteins were synthesized in vitro using the TnT-
coupled reticulocyte lysate system (Promega). GST, GST-hERK and
GST-hERL proteins were induced, solubilized, and bound to gluta-
thione beads following the manufacturer’s instruction (Pharmacia
LKB). After binding to glutathione beads, 15 Wl of the suspension
was incubated with 1^2 Wl of the appropriate 35S-labeled, in vitro
translated protein for 1 h in 500 Wl of NETN (20 mM Tris-HCl,
pH 7.5, 100 mM KCl, 0.7 mM EDTA, 0.5% Nonidet P-40, 1 mM
phenylmethylsulfonyl £uoride). Following incubation, the beads were
washed three times with NETN. Bound proteins were eluted with 20 Wl
of 1USDS-PAGE bu¡er (50 mM Tris-HCl, pH 6.8, 100 mM dithio-
threitol, 2% SDS, 0.1% bromophenol blue, 10% glycerol) and electro-
phoretically separated in a SDS/7.5% polyacrylamide gel.
3. Results
In order to investigate the possibility that ERK and ERL
mutually enhance the E2-dependent transcriptional activity on
an ERE, pCXN2-hERK and pCXN2-hERL were co-trans-
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Fig. 2. Structures of ERK1^530 and ERL1^481. A: Comparison around the C-terminal truncated portion of ERK1^530 and ERL1^481. The hu-
man ERK deduced amino acid sequence (shown above) and corresponding ERL amino acids (shown below) are depicted. Asterisks indicate
identity between the sequences. B: Comparison between ERK1^530, ERL1^481 and wild-type ERK and ERL proteins. The functional A^E/F
domains are schematically represented, with the numbers of amino acid residues as indicated.
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fected with EREG-CAT reporter construct (see Section 2). In
COS-7 cells transfected with only ERK or ERL, relative CAT
activity increased 25-fold and 9-fold, respectively, upon stim-
ulation with 1037 M E2 (Fig. 1A). Transcriptional activity of
various ratios of co-expressed ERK and ERL was shown in
Fig. 1B.
Previous studies have shown that ERK1^530 acts as a dom-
inant negative mutant against ERK transactivation [8]. Here,
we constructed ERK1^530 expression vector and its equivalent
ERL mutant from the sequence homology around their trun-
cation sites (Fig. 2A), that is ERL1^481 as shown in Fig. 2B.
Interestingly, ERK1^530 inhibited the ligand-dependent trans-
activation by ERL (Fig. 3B) as well as that by ERK (Fig. 3A).
Moreover, ERL1^481 inhibited not only the transactivation
by ERL (Fig. 3D) but also that by ERK (Fig. 3C).
In vitro translated products of ERK1^530 consisted of two
proteins of 59 kDa and 48 kDa, both of which were pulled
down using the GST-fused ERK or ERL protein (Fig. 4, lanes
1, 5, 7). As for ERL1^481 products, 54 kDa and 51 kDa
proteins were detected, both of which were pulled down by
GST-hERK or hERL protein (Fig. 4, lanes 2, 6, 8). In vitro
translated ERK1^530 and ERL1^481 were not pulled down
with the GST protein alone (Fig. 4, lanes 3, 4).
4. Discussion
Recently, we [11] and others [6,7] demonstrated the hetero-
dimerization between ERK and ERL in vivo and in vitro.
Since the formation of ERK/ERL heterodimers was estab-
lished, we then tried to ascertain the functional interaction
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Fig. 3. Inhibitory e¡ects of ERK1^530 and ERL1^481 against the transactivation by wild-type ERs. Dose-dependent inhibitory e¡ects of
ERK1^530 against the transactivations by ERK (A) and ERL (B) of the ERE-GCAT reporter are shown by CAT assay. Dose-dependent inhibi-
tory e¡ects of ERL1^481 against the transactivations by ERK (C) and ERL (D) of the ERE-GCAT reporter are also shown. ERK, ERL,
ERK1^530 and ERL1^481 are the abbreviations of pCXN2-hERK, pCXN2-hERL, pCXN2-hERK1^530 and pCXN2-hERL1^481, respectively.
Fig. 4. GST pull-down assay. ERK1^530 and ERL1^481 proteins
were synthesized in vitro using the TnT-coupled reticulocyte lysate
system (Promega), shown in lanes 1 and 2 at the amount of 10% of
input. After binding of GST, GST-hERK and GST-hERL proteins
to glutathione beads, 15 Wl of the suspension was incubated with 1^
2 Wl of the appropriate 35S-labeled, in vitro translated protein for
1 h in 500 Wl of NETN bu¡er. Bound proteins were eluted and elec-
trophoretically separated in a SDS/7.5% polyacrylamide gel.
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between ERK and ERL in vivo. Co-transfection experiments
have shown that they enhance the mutual transcriptional ac-
tivity independently rather than synergistically.
In order to demonstrate their functional heterodimeriza-
tion, we utilized the dominant negative activities of the C-
terminal truncated ER mutants, ERK1^530 and ERL1^481,
against wild-type ERK and ERL. Both mutants were found
to inhibit the transactivation by ERK as well as by ERL. The
inhibitory e¡ect of C-terminal truncated ER mutants may be
explained by the following three mechanisms: competition for
ERE binding, formation of inactive heterodimers with wild-
type ER and speci¢c transcriptional silencing [8,16]. All these
mechanisms are possible for their dominant negative e¡ect
and they are not mutually exclusive. Because ERK1^530 re-
tains the region important for ER dimerization (500^520 aa)
[17] and ERL1^481 also possesses the corresponding region,
their interactions with wild-type ERs would be intact. To
show heterodimerization between these mutant ERs and
wild-type ERs, the GST pull-down assay was performed. Be-
cause GST-fused full-length ERK was not soluble, we here
utilized GST fusion protein with N-terminal truncated ERK.
The protein interactions were demonstrated clearly as shown
in Fig. 4. Thus, it was shown that both ERK1^530 and ERL1^
481 can act by heterodimerization with wild-type ERK as well
as ERL, at least. The sizes of the ERL1^481 protein translated
in vitro were approximately 54 kDa and 51 kDa, suggesting
its translational initiation from both the ¢rst ATG and its
downstream ATGs. As for ERK1^530, the 58 kDa protein
was translated in vitro as well as the 47 kDa protein, both
of which were detectable by the anti-ERK monoclonal anti-
body D547 [18,19] (data not shown). The 47 kDa protein
might be translated from downstream ATGs of ERK1^530
or its degradation product.
To characterize the cross-talk between ERK and ERL in
detail, it is also necessary to investigate the distinct functions
of ERK and ERL. The homology of the N-terminal A/B do-
mains including the activation function 1 (AF-1) of ERK and
ERL is only 30% [11], which might be responsible for the
selectivity of the tamoxifen antagonism only observed in
ERK [12]. Moreover, E2-dependent transactivation properties
of ERK and ERL on AP1 were recently reported to be in
opposite modes [20]. The speci¢city of the transactivational
regulation between ERK and ERL was also reported in terms
of the distinct activity of cofactors, i.e. SRC-1 [5]. These ¢nd-
ings suggest the possibility that di¡erent transactivational
mechanisms are present in ERK and ERL because of their
di¡erent AF-1 and AF-2 activities. Heterodimerization of
these receptors would provide another dimension to the com-
plex regulation of target tissues by estrogen, which is yet to be
elucidated.
In conclusion, we have made ERK and ERL mutants which
block the function of both ERK and ERL at the transactiva-
tion level. Moreover, we have shown evidence for the ¢rst
time for the cross-interaction of these mutants with wild-
type ERK and ERL. These dominant negative mutants de-
scribed here may be utilized as a tool to investigate the phys-
iological role of estrogen receptor in vivo, inhibiting both
signal pathways of ERs.
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